(Q42116604)

16 October 2017

An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function (English)

1 reference

16 October 2017

1 reference

P J Tiseo

1

1 reference

16 October 2017

R Vargas

series ordinal

2

1 reference

16 October 2017

C A Perdomo

series ordinal

3

1 reference

16 October 2017

L T Friedhoff

series ordinal

4

1 reference

16 October 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

British Journal of Clinical Pharmacology

16 October 2017

1 reference

16 October 2017

46 Suppl 1

1 reference

16 October 2017

51-55

1 reference

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

Tacrine: first drug approved for Alzheimer's disease

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1873809

Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects

17 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9839767

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1046/J.1365-2125.1998.0460S1051.X

1 reference

16 October 2017

1 reference

16 October 2017

1 reference